Takeda Pharmaceutical Company of Japan has posted lower net profit of
Yen 34 billion during the first quarter ended June 2014 as against Yen
36 billion in the corresponding period of last year due to stagnant
sales, higher input costs and launch of new products in the US. Its
revenue improved marginally by 0.2 per cent to Yen 411 billion from Yen
410 billion. Its earnings per share worked out to Yen 42.40 as compared
to Yen 45.53 in the last period.
The company's sales of Ethical drugs improved only by 0.5 per cent to Yen 372 billion as its sales in Japan declined by 2.2 per cent to Yen 138 billion. Contribution from sales increase of products launched in and after 2010 such as Asilva and Nesina could not fully absorb the decrease in sales mainly due to the National Health Insurance price reduction and the penetration of generic products. However, its overseas sales improved by 2.7 per cent to Yen 234 billion due to higher sales of Velcade in the US and Pantoprazole in emerging markets including Asia.
The company's sales of Ethical drugs improved only by 0.5 per cent to Yen 372 billion as its sales in Japan declined by 2.2 per cent to Yen 138 billion. Contribution from sales increase of products launched in and after 2010 such as Asilva and Nesina could not fully absorb the decrease in sales mainly due to the National Health Insurance price reduction and the penetration of generic products. However, its overseas sales improved by 2.7 per cent to Yen 234 billion due to higher sales of Velcade in the US and Pantoprazole in emerging markets including Asia.
No comments:
Post a Comment